News
Stock markets have rallied after U.S. President Donald Trump announced a ceasefire in the Israel-Iran conflict, although the ...
Novo Nordisk, the company behind blockbuster weight-loss drugs like Ozempic and Wegovy, had a deal with Hims & Hers that ...
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...
The home builder says it has worked to lower its build times and reduce direct construction costs as it navigates softer market conditions. The airline's relisting comes against the backdrop of an ...
Teladoc Health stock price surged by over 14% on Monday, its best single-day gain since April 9. What next for the TDOC share ...
Futures data from IG suggests a positive start for European markets, with London's FTSE looking set to open 0.3% higher at ...
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
6h
Stocktwits on MSNHims & Hers Stock Rebounds After-Hours After Novo Nordisk Split Triggers Record Plunge — Retail Traders Stay LoyalHims & Hers Health Inc. (HIMS) rebounded 4.38% in after-hours trading Monday, partially clawing back losses after the stock ...
7h
Asianet Newsable on MSNHims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’CEO Andrew Dudum on Monday expressed disappointment at Novo Nordisk’s (NVO) decision to cancel its collaboration with the ...
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results